By inhibiting this interaction, FOXO4-DRI allows reactivation of the apoptotic pathway in non-proliferative senescent cells, leading to their selective elimination without damaging healthy tissue
Some clinicians use an alternative calculation of 0.6 to 0.8 grams per pound of ideal body weight , which yields similar targets
However, Ozempic and Wegovy have gone through the FDA approval process, whereas compounded semaglutide is not FDA-approved and does not undergo safety, effectiveness, or manufacturing review by FDA
What else can I say
Data availability A total of 262 studies analyzed in this study were identified through ClinicalTrials.gov, the International Clinical Trials Registry Platform, Cochrane Central Register of Controlled Trials, PubMed, and Web of Science